Inhibition of Yes-Associated Protein by Verteporfin Ameliorates Unilateral Ureteral Obstruction-Induced Renal Tubulointerstitial Inflammation and Fibrosis
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Yes-associated protein (YAP) activation after acute ischemic kidney injury might be related to interstitial fibrosis and impaired renal tubular regeneration. Verteporfin (VP) is a photosensitizer used in photodynamic therapy to treat age-related macular degeneration. In cancer cells, VP inhibits TEA domain family member (TEAD)-YAP interactions without light stimulation. The protective role of VP in unilateral ureteral obstruction (UUO)-induced renal fibrosis and related mechanisms remains unclear. In this study, we investigate the protective effects of VP on UUO-induced renal tubulointerstitial inflammation and fibrosis and its regulation of the transforming growth factor-β1 (TGF-β1)/Smad signaling pathway. We find that VP decreased the UUO-induced increase in tubular injury, inflammation, and extracellular matrix deposition in mice. VP also decreased myofibroblast activation and proliferation in UUO kidneys and NRK-49F cells by modulating Smad2 and Smad3 phosphorylation. Therefore, YAP inhibition might have beneficial effects on UUO-induced tubulointerstitial inflammation and fibrosis by regulating the TGF-β1/Smad signaling pathway.
Overview
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Verteporfin, a direct inhibitor of YAP-TEAD binding and transcriptional activity, significantly reduced collagen I and fibronectin expression and ameliorated fibrosis severity in a unilateral ureteral obstruction (UUO) kidney fibrosis model, while improving epithelial structural integrity (146, 147).”
From The mechanotransduction-immune axis in organ fibrosis: dual regulatory mechanisms and translational therapeutic perspectives (2025) · doi:10.3389/fimmu.2025.1670213 · cites this paper as [147]
Citations
Cites
Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., Casey, D. C., Charlson, F. J., Chen, A. Z., Coates, M. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31012-1 · Cited by 6,596
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 1×
“The infiltration of polymorphonuclear neutrophils and monocytes is characteristic of the initial inflammatory response to injury [28,29].”
BackgroundTGF-β: the master regulator of fibrosis
Meng, X.-M., Nikolic-Paterson, D. J., & Lan, H. Y. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.48 · Cited by 3,528
Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators
Serhan, C. N., Chiang, N., & Van Dyke, T. E. (2008) · Nature Reviews Immunology · doi:10.1038/nri2294 · Cited by 2,932 · cited 1×
“The infiltration of polymorphonuclear neutrophils and monocytes is characteristic of the initial inflammatory response to injury [28,29].”
BackgroundThe Biology of YAP/TAZ: Hippo Signaling and Beyond
Piccolo, S., Dupont, S., & Cordenonsi, M. (2014) · Physiological Reviews · doi:10.1152/physrev.00005.2014 · Cited by 1,802 · cited 2×
“YAP is related to nephron morphogenesis, and TAZ inactivation causes polycystic kidney disease [14].”
BackgroundMechanisms of Hippo pathway regulation
Meng, Z., Moroishi, T., & Guan, K.-L. (2016) · Genes & Development · doi:10.1101/gad.274027.115 · Cited by 1,667 · cited 12×
“Once the Hippo pathway has been activated, it limits tissue growth and cell proliferation through the phosphorylation and degradation of YAP/TAZ.”
BackgroundInfluentialLiu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S.-J., Anders, R. A., Liu, J. O., & Pan, D. (2012) · Genes & Development · doi:10.1101/gad.192856.112 · Cited by 1,452 · cited 1×
“showed that VP inhibits TEA domain family member (TEAD)–YAP interactions in cancer cells without light stimulation [16].”
BackgroundThe Hippo Pathway: Biology and Pathophysiology
Ma, S., Meng, Z., Chen, R., & Guan, K.-L. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111829 · Cited by 1,387 · cited 2×
“In contrast, when the Hippo pathway is turned off, YAP/TAZ is dephosphorylated and translocated into the nucleus to induce target gene transcription [12,13].”
BackgroundThe Hippo–YAP pathway in organ size control and tumorigenesis: an updated version
Zhao, B., Li, L., Lei, Q., & Guan, K.-L. (2010) · Genes & Development · doi:10.1101/gad.1909210 · Cited by 1,144
Chapter 1: Definition and classification of CKD
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.64 · Cited by 1,110
Cited by
The Hippo signalling pathway and its implications in human health and diseases
Fu, M., Hu, Y., Lan, T., Guan, K.-L., Luo, T., & Luo, M. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01191-9 · Cited by 742
Epithelial–mesenchymal transition in tissue repair and degeneration
Youssef, K. K., & Nieto, M. A. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00733-z · Cited by 159
“Verteporfin, a drug that blocks the interaction between YAP/TAZ and their effector TEAD, reduces TGFβ–SMAD signalling, decreases inflammation and myofibroblast activation in a model of murine renal fibrosis 220 (Fig.”
YAP/TAZ: Molecular pathway and disease therapy
Wei, Y., Hui, V. L. Z., Chen, Y., Han, R., Han, X., & Guo, Y. (2023) · MedComm · doi:10.1002/mco2.340 · Cited by 122
Yeh, T.-H., Tu, K.-C., Wang, H., & Chen, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031755 · Cited by 120
“…of 22 Another compound, Vertepor fi n (VP), a photosensitizer used in treating age-related macular degeneration, can bind to YAP, disrupting its interaction with TEAD, which might improve renal tubulointerstitial in fl ammation and fi brosis [139,140]. modulation of the Hippo signaling pathway [138].”
BackgroundDecellularized Disc Hydrogels for hBMSCs tissue-specific differentiation and tissue regeneration
Peng, Y., Qing, X., Lin, H., Huang, D., Li, J., Tian, S., Liu, S., Lv, X., Ma, K., Li, R., et al. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.03.014 · Cited by 90
The critical role of the Hippo signaling pathway in kidney diseases
Sun, Y., Jin, D., Zhang, Z., Jin, D., Xue, J., Duan, L., Zhang, Y., Kang, X., & Lian, F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.988175 · Cited by 36
Jin, J., Li, W., Wang, T., Park, B., Park, S. K., & Kang, K. P. (2022) · Cells · doi:10.3390/cells11091477 · Cited by 33
Self-citationChoi, S., Hong, S. P., Bae, J. H., Suh, S. H., Bae, H., Kang, K. P., Lee, H. J., & Koh, G. Y. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000075 · Cited by 35
“In addition, YAP/TAZ inhibition by verteporfin ameliorates renal fibrosis after unilateral ureteral obstruction in adult mice (19).”
BackgroundSelf-citationZhang, X., Zhang, S., Qi, J., Zhao, F., Lu, Y., Li, S., Wu, S., Li, P., & Tan, J. (2023) · Stem Cell Research & Therapy · doi:10.1186/s13287-023-03339-y · Cited by 33
(2025) · doi:10.3389/fimmu.2025.1670213 · Cited by 29
Hu, Q., Li, H., Ye, Z., Wei, Z., & Ao, J. (2022) · Materials Today Bio · doi:10.1016/j.mtbio.2022.100523 · Cited by 30
Zhao, M., Ma, Q., Zhao, Z., Guan, X., & Bai, Y. (2021) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2021.105263 · Cited by 26
Li, X., Zeng, M., Liu, J., Zhang, S., Liu, Y., Zhao, Y., Wei, C., Yang, K., Huang, Y., Zhang, L., et al. (2023) · BMC Medical Genomics · doi:10.1186/s12920-023-01494-y · Cited by 21
“In addition, verteporfin produced protective effects against UUO-induced renal tubulointerstitial inflammation and fibrosis by suppressing the TGF-β1/Smad signaling pathway [83].”
BackgroundRebolledo, D. L., Acuña, M. J., & Brandan, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105234 · Cited by 20
“As a possible therapeutic target for kidney diseases, YAP inhibition using verteporfin effectively decreased renal fibrosis in mice, reducing TGF-β signaling and CCN2/CTGF levels [129].”
BackgroundThe Hippo pathway and its correlation with acute kidney injury
Zhang, C., 上海交通大学附属第一人民医院肾内科, 上. 2., Li, C., Xu, K., Zheng, Z., Cheng, G., Wu, H., Liu, J., & 复旦大学基础医学院病理科, 上. 2. (2022) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2022.110 · Cited by 21
“EMT is the process by which a polarized epithelial cell adopts a mesenchymal cell phenotype, and includes enhanced migratory ability, invasiveness, resistance to apoptosis, and secretion of ECM (Kalluri & Weinberg, 2009).”
Verteporfin‐Loaded Bioadhesive Nanoparticles for the Prevention of Hypertrophic Scar
Wang, P., Peng, Z., Yu, L., Liu, Y., Wang, H., Zhou, Z., Liu, H., Hong, S., Nie, Y., Deng, Y., et al. (2023) · Small Methods · doi:10.1002/smtd.202301295 · Cited by 20
Hu, Q., Zhu, B., Yang, G., Jia, J., Wang, H., Tan, R., Zhang, Q., Wang, L., & Kantawong, F. (2022) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2022.12.001 · Cited by 17
Kidney Inflammation, Injury and Regeneration 2020
Baer, P. C., Koch, B., & Geiger, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115589 · Cited by 17
“The study showed that verteporfin decreases the UUO-induced increase in tubular injury, inflammation and extracellular matrix deposition in mice [12].”
BackgroundChen, F., Kang, N.-W., Wungcharoen, T., Jiang, L., Basco, C. A., Garcia-Sanchez, J., Lin, D., Seo, Y. A., Jang, K., Myung, D. J., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.02.051 · Cited by 14
Yang, J., Wu, D., Li, J., Zhao, C., Zhu, L. Q., Xu, C., & Xu, N. (2023) · Macromolecular Bioscience · doi:10.1002/mabi.202300165 · Cited by 12
Qi, C., Hu, Y., Zeng, M., Chen, H., Shi, J., Jue, H., Zhao, Z., Liu, J., Zhang, Z., Xu, Y., et al. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121186 · Cited by 13
The critical role of the Hippo signaling pathway in renal fibrosis
Zhao, C., Wang, H., Xu, C., Fang, F., Gao, L., Zhai, N., Zhong, Y., & Wang, X. (2025) · Cellular Signalling · doi:10.1016/j.cellsig.2025.111661 · Cited by 9
Cavanzo, N. P., Riesmeijer, S. A., Holt-Kedde, I. L., Werker, P. M. N., Piersma, B., Olinga, P., & Bank, R. A. (2022) · Scientific Reports · doi:10.1038/s41598-022-18116-9 · Cited by 9
Kosakai, W., Inoue, T., Sato, T., & Okada, H. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.111029 · Cited by 5
“This is consistent with previous studies showing that YAP1 expression was upregulated in injured renal proximal tubular epithelial cells and localized to the nucleus (36, 47).”
Li, Y., Gao, X., Chen, Y., Li, H., Tang, J., & Sun, W. (2025) · European Journal of Histochemistry · doi:10.4081/ejh.2025.4182 · Cited by 4
Sun, M.-C., Zuo, F., Wang, Y.-Z., Ren, X.-L., Lu, H.-S., Zheng, M.-B., Zhang, H., Liu, H., Lu, C.-C., Shen, C.-W., et al. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01793-x · Cited by 3
Ouyang, X., Yu, W. W., Wang, J., Wang, H., Wang, S., Wang, G., Sun, B., Xu, C., Liu, Y., Wang, W., et al. (2023) · Materials & Design · doi:10.1016/j.matdes.2023.112075 · Cited by 3
Fung, M. V., Armstrong, J. J., Zhang, R., Vinokurtseva, A., Liu, H., & Hutnik, C. M. L. (2024) · Bioengineering · doi:10.3390/bioengineering11020142 · Cited by 3
“It was demonstrated that YAP inhibition through verteporfin decreases contractility of trabecular meshwork cells [50], and previous reports have shown that verteporfin mitigates kidney myofibroblast transdifferentiation [51].”
BackgroundSu, H., & Song, K. (2026) · Biomolecules · doi:10.3390/biom16040559 · Cited by 3
“For example, verteporfin (VP) reduces myofibroblast activation and proliferation in the kidneys by modulating the phosphorylation of Smad2 and Smad3, attenuating renal inflammation and ECM deposition [141].”
Provoking myofibroblast death: Strategies to resolve fibrosis and remodel tumor microenvironment
Shalini, T., & Sudhandiran, G. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i12.111086 · Cited by 1
FGFR1/YAP1 signaling in endothelial cells drives renal fibrosis and offers a therapeutic target
Jiang, X. M., Ren, Y., Yan, M., Li, M., Cao, H., & Shao, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1766265 · Cited by 2
“Verteporfin, a clinical agent used in ophthalmologic photodynamic therapy, is frequently employed as a experimental YAP1 inhibitor in renal fibrosis research (Szeto et al., 2016; Jin et al., 2020; Chen and Harris, 2016; Chen et al., 2020).”
Targeting YAP: mechanistic breakthroughs and therapeutic prospects in reversing organ fibrosis
Fu, K., Cao, M., Wang, Y., Luo, J., & Yuan, W. (2026) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-026-05540-y · Cited by 1
“Nevertheless, its clini - cal application value still requires human trials [121, 202].”
Targeting the lncRNA PVT-1-Hippo signaling axis in kidney diseases: an emerging therapeutic paradigm
Kulkarni, H. V., & Gaikwad, A. B. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12586-0 · Cited by 1
Wang, B., Wang, X., Dong, Y., Liu, X., Xu, L., Liu, Y., Wu, Y., Wang, C., & Liu, H. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02594-3 · Cited by 1
“…TGF-β1/Smad signaling pathway plays an important role in UUO-induced renal fibrosis and the activated Smad2/3 proteins are key events in this signaling pathway (Jin et al. 2020; Wang et al. 2020a; Zhang et al. 2022), we therefore determine the phosphorylation of Smad2/3 levels in different groups.”
Kidney Inflammation, Injury and Regeneration 2020
Baer, P. C., Koch, B., & Geiger, H. (2021) · MDPI eBooks · doi:10.3390/books978-3-0365-2369-9
Kidney Inflammation, Injury and Regeneration
Baer, P. C., Koch, B., & Geiger, H. (2020) · MDPI eBooks · doi:10.3390/books978-3-03928-539-6
Implication de YAP/TAZ dans l'inflammation
Caire, R. (2021) · theses.fr (ABES) · doi:10.70675/81dd5a90z427bz4a8aza3e1z898830595b60
The Hippo pathway: potential target for immunotherapy of crescentic glomerulonephritis
Kuang, H., Cui, Z., Zhao, M., & Jia, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1672128
Zhang, X., Zhang, S., Qi, J., Zhao, F., Lu, Y., Li, S., Wu, S., Li, P., & Tan, J. (2024) · Figshare · doi:10.6084/m9.figshare.26585769
Zhang, X., Zhang, S., Qi, J., Zhao, F., Lu, Y., Li, S., Wu, S., Li, P., & Tan, J. (2024) · Figshare · doi:10.6084/m9.figshare.26585766
Zhang, X., Zhang, S., Qi, J., Zhao, F., Lu, Y., Li, S., Wu, S., Li, P., & Tan, J. (2024) · Figshare · doi:10.6084/m9.figshare.26585772
UNDERSTANDING HOW ACTIVINS CONTRIBUTE TO TGFß1 PROFIBROTIC SIGNALIING IN CHRONIC KIDNEY DISEASE
Soomro, A. (2023) · MacSphere (McMaster University) · doi:10.71548/10225
Deficiency of exocyst complex component Exoc5 exacerbates the progression of kidney fibrosis
Lim, H. J., Han, Y. K., Noh, M. R., Park, Y. R., Jang, S. Y., Lipschutz, J. H., & Park, K. M. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01649-8
The critical role of YAP and TAZ in tubular homeostasis
Ruscica, B. (2024) · theses.fr (ABES) · doi:10.70675/f88d17d8z4673z44c8zb7d3zf1efb9ddfc2f
Amicone, L., Cicchini, C., Petti, F., & Marchetti, A. (2026) · Genes · doi:10.3390/genes17080851
“…pharmacological inhibitors of the YAP/TAZ– TEAD complex, such as verteporfin [168], have shown success in attenuating EMT, stem-like traits and fibrotic progression [169,170], thus reinforcing the central role of YAP/TAZ in these processes and supporting their potential as therapeutic targets.”
Metadata
- Authors
- Jin, J., Wang, T., Park, W., Li, W., Kim, W., Park, S. K., & Kang, K. P.
- Affiliations
- Jeonbuk National University Hospital (KR)
- Corresponding author
- Park, Sung Kwang
- Kang, Kyung Pyo
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2020-10-31
- Volume
- 21
- Issue
- 21
- Pages
- 8184
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7662854
- OpenAlex
- W3095066918
- Cited by
- 43
- References
- 44
- Citations by year
- 2026: 7 · 2025: 7 · 2024: 7 · 2023: 8 · 2022: 8 · 2021: 5 · 2020: 1
- FWCI
- 2.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- National Research Foundation of Korea (NRF-2018R1D1A1B07045790, NRF- 2017R1D1A3B03035494)
- Fund of Biomedical Research Institute, Jeonbuk National University Hospital (CUH2020-0014)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Hippo pathway signaling and YAP/TAZ
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Keywords
- verteporfin, YAP, unilateral ureteral obstruction, tubulointerstitial fibrosis, tubulointerstitial inflammation, TGF-β1/Smad signaling, myofibroblast activation, extracellular matrix deposition, acute kidney injury, kidney regeneration
- MeSH terms
- Verteporfin, YAP-Signaling Proteins, Animals, Cells, Cultured, Disease Models, Animal, Fibrosis, Inflammation, Kidney Diseases, Male, Mice, Inbred C57BL, Ureteral Obstruction, Photosensitizing Agents, Cell Cycle Proteins, Adaptor Proteins, Signal Transducing, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.